Breast Cancer pp 161-174 | Cite as

Hormonal Therapy of Breast Cancer

  • Halle C. F. Moore
  • Kevin R. Fox
Part of the Current Clinical Oncology book series (CCO)


Studies of breast cancer epidemiology suggest an important role of hormonal factors in the development of breast cancer. An individual’s risk of developing breast cancer is clearly correlated with the timing of menarche and menopause, parity, age of first pregnancy, use of exogenous estrogens, and female gender. Given the importance of the endocrine environment in the establishment of breast cancer, it is not surprising that hormonal manipulations have become a crucial aspect of therapy for this disease.


Breast Cancer Endometrial Cancer Metastatic Breast Cancer Aromatase Inhibitor Advanced Breast Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Atkins H, Falconer MA, Hayward JL, et al (1966) The timing of adrenalectomy and of hypophysectomy in the treatment of advanced breast cancer. Lancet. 1, 827–830.PubMedCrossRefGoogle Scholar
  2. 2.
    The Australian and New Zealand Breast Cancer Trials Group (1986) A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy geven sequentially or in combination. J. Clin. Oncol. 4, 186–193.Google Scholar
  3. 3.
    Cocconi G, De Lisi V, Boni C, et al (1983) Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. Cancer 51, 581–588.PubMedCrossRefGoogle Scholar
  4. 4.
    Ingle JN, Twito DI, Schaid DJ, et al (1988) Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer. J. Clin. Oncol. 6, 825–831.PubMedGoogle Scholar
  5. 5.
    Ingle JN, Green SJ, Ahmann DL, et al (1986) Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J. Clin. Oncol. 4, 958–964.PubMedGoogle Scholar
  6. 6.
    Ellis M, (1998) Selective aromatase inhibitos: current indication and future perspectives. Dis. Breast Upd. 2, 1–11.Google Scholar
  7. 7.
    Ravdin PM, Green S, Dorr TM, et al (1992) Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective southwest oncology group study. J. Clin. Oncol. 10, 1284–1291.PubMedGoogle Scholar
  8. 8.
    Buzdar AU, Hortobagyi GN, Frye D, et al (1994) Bioequivalence of 10-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer. J. Clin. Oncol. 12, 50–54.PubMedGoogle Scholar
  9. 9.
    Hayes DF, Van Zyl JA, Hacking A, et al (1995) Randomized comparison of tamoxifen and two separate doses of toremifine in postmenopausal patients with metastatic breast cancer. J. Clin. Oncol. 13, 2556–2566.PubMedGoogle Scholar
  10. 10.
    Vogel CL, Shemano I, Schoenfelder J, et al (1993) Multicenter phase II efficacy trial of toremifine in tamoxifen-refractory patients with advanced breast cancer. J. Clin. Oncol. 11, 345–350.PubMedGoogle Scholar
  11. 11.
    Lipton A, Santen RJ, (1973) Medical adrenalectomy using aminoglutethamide and dexamethasone in advanced breast cancer. Cancer 33, 503–512.CrossRefGoogle Scholar
  12. 12.
    Jonat W, Howell A, Blomqvist C, et al (1996) A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur. J. Cancer 32A, 404–412.CrossRefGoogle Scholar
  13. 13.
    Howell A, Buzdar A, Jonat W, et al (1997) Significantly improved survival with Arimidex’ (anastrozole (AN)) compared with megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC): updated results of two randomixed trials. Breast Cancer Res. Treat. 46, 27.Google Scholar
  14. 14.
    Dombernowsky P, Smith I, Falkson G, et al (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol. 16, 453–461.PubMedGoogle Scholar
  15. 15.
    Kaufman M, Bajetta L, Fein L, et al (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J. Clin. Oncol. 18, 1399–1411.Google Scholar
  16. 16.
    Lonning P, Bajetta E, Murray R, et al (2000) Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase III trial. J. Clin. Oncol. 18, 2234–2244.PubMedGoogle Scholar
  17. 17.
    Muss HB, Paschold EH, Black WR, et al (1985) Megestrol acetate v tamoxifen in advanced breast cancer: a phase III trial of the Piedmont Oncology Association (POA). Sem. Oncol. XII, 55–61.Google Scholar
  18. 18.
    Muss HB, Case DL, Atkins JN, et al (1994) Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer. J. Clin. Oncol. 12, 1630–1638.PubMedGoogle Scholar
  19. 19.
    Bonneterie J, Thurliman B, Robertson J, et al (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J. Clin. Oncol. 18, 3748–3757.Google Scholar
  20. 20.
    Nabholz J, Buzdar A, Pollak M, et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J. Clin. Oncol. 18, 3758–3767.Google Scholar
  21. 21.
    Mourisden H, Gershanovich M, Sun Y, et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the international letrozole breast cancer group. J. Clin. Oncol. 19, 2596–2606.Google Scholar
  22. 22.
    Mourisden H, Sun Y, Gershanovich M, et al (2001) Final survival analysis of the double-blind, randomized multinational phase III trial of letrozole (Femara) compared to tamoxifen as first-line therapy for advanced breast cancer. Breast Cancer Res Treat 69, 211.Google Scholar
  23. 23.
    Buzdar A, Jonat W, Howell A, et al (1996) Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J. Clin. Oncol. 14, 2000–2011.PubMedGoogle Scholar
  24. 24.
    Kaufmann M, Jonat W, Kleeberg U, et al (1989) Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J. Clin. Oncol. 7, 1113–1119.PubMedGoogle Scholar
  25. 25.
    Taylor CW, Green S, Dalton WS, et al (1998) Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.. 1. Clin. Oncol. 16, 994–999.Google Scholar
  26. 26.
    Buchanan RB, Blarney RW, Dunant KR, et al (1986) A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J. Clin. Oncol. 4, 1326–1330.PubMedGoogle Scholar
  27. 27.
    Martoni A, Longhi A, Canova N, et al (1991) High-dose medroxyprogesterone acetate versus oophorectomy as first-line therapy of advanced breast cancer in premenopausal patients. Oncol. 48, 1–6.CrossRefGoogle Scholar
  28. 28.
    Klijn JG, Beex LV, Mauriac L, et al (2000) Combined treatment with buserelin and tamoxifen in premenepausal metastatic breast cancer: a randomized study. J. Nat. Cancer Inst. 92, 903–911.PubMedCrossRefGoogle Scholar
  29. 29.
    Patey DH, Nabarro JDN, (1970) Early (“prophylactic”) oophorectomy and adrenalectomy in carcinoma of the breast: a ten-year follow-up. Br. J. Cancer 24, 16–21.PubMedCrossRefGoogle Scholar
  30. 30.
    Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339, 1–15, 71–85.Google Scholar
  31. 31.
    Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351, 1451–1467.CrossRefGoogle Scholar
  32. 32.
    Fisher B, Dignam J, Bryant J, et al (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Nat. Cancer Inst. 88, 1529–1541.PubMedCrossRefGoogle Scholar
  33. 33.
    Fisher B, Redmond C, Legault-Poisson S, et al (1990) Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J. Clin. Oncol. 8, 1005–1018.PubMedGoogle Scholar
  34. 34.
    Fisher B, Dignam J, Wolmark N, et al (1997) Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J. Nat Can. Inst. 89, 1673–1682.CrossRefGoogle Scholar
  35. 35.
    Carlomagno C, Perrone F, Gallo C, et al (1996) c-erbB2 overexpression decreases the beneifit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J. Clin. Oncol. 14, 2702–2708.PubMedGoogle Scholar
  36. 36.
    Ravdin PM, Green S, Albain KS, et al (1998) Initial report of the SWOG biological correlative study of c-erb2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone. Proc. ASCO 17, 97a.Google Scholar
  37. 37.
    Wolmark N, Dignam J, Fisher B, (1990) The addition of tamoxifen to lumpectomy and radiotherapy in the treatment of ductal carcinoma in situ (DCIS): preliminary results of NSABP protocol B-24. Breast Cancer Research and Treatment 50, 227 (abst).Google Scholar
  38. 38.
    Ragaz J, Coldman A, (1998) Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivaors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J. Clin. Oncol. 16, 2018–29024.PubMedGoogle Scholar
  39. 39.
    Mamounas EP, Bryant J, Fisher B, et al (1998) Primary breast cancer (PBC) as a risk factor for subsequent contralateral breast cancer (CBC): NSABP experience from nine randomized adjuvant trials. Breast Cancer Res. Treat. 50, 230 (abst).Google Scholar
  40. 40.
    Fisher B, Costantino JP, Wickerham DL, et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjvuant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90, 1371–1388.PubMedCrossRefGoogle Scholar
  41. 41.
    Veronesi U, Maisonneuve P, Costa A, et al (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the italian randomised trial among hysterectomised women. Lancet 352, 93–97.PubMedGoogle Scholar
  42. 42.
    Powles T, Eeles R, Ashley S, et al (1998) Interim analysis of the incidence of breast cancer in the royal mars-den hospital tamoxifen randomised chemoprevention trial. Lancet 352, 98–101.PubMedGoogle Scholar
  43. 43.
    Cummings SR, Norton L, Eckert S, et al (1998) Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) Trial. Proc. Am. Soc. Hematol. 17, 2a.Google Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Halle C. F. Moore
  • Kevin R. Fox

There are no affiliations available

Personalised recommendations